Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer

Alessandro De Vita, Chiara Liverani, Roberto Molinaro, Jonathan O. Martinez, Kelly A. Hartman, Chiara Spadazzi, Giacomo Miserocchi, Francesca Taraballi, Michael Evangelopoulos, Federica Pieri, Alberto Bongiovanni, Laura Mercatali, Ennio Tasciotti, Toni Ibrahim

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel extracellular matrix (ECM)-targeting nanotherapeutic was engineered using a lipid-based nanoparticle chemically linked to an inhibitor of the ECM-related enzyme, lysyl oxidase 1 (LOX), that inhibits the crosslinking of elastin and collagen fibers. We demonstrated that, when the conjugated vesicles were loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breast cancer (TNBC) cell growth was observed both in vitro and in vivo. Moreover, in vivo results displayed prolonged survival, minimal cytotoxicity, and enhanced biocompatibility compared to free epirubicin and epirubicin-loaded nanoparticles. This all-in-one nano-based ECM-targeting chemotherapeutic may provide a key-enabling technology for the treatment of TNBC.

Original languageEnglish (US)
Article number5107
Pages (from-to)5107
JournalScientific Reports
Issue number1
StatePublished - Mar 3 2021

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer'. Together they form a unique fingerprint.

Cite this